Baidu
map

Sci Signal:不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育

2020-03-05 不详 MedSci原创

成纤维细胞生长因子(FGFs) 9和10在肺发育的假腺期必不可少。间皮细胞产生的FGF9主要负责间质细胞的生长,而上皮细胞产生的FGF9和间质细胞产生的FGF10则指导肺上皮细胞的发育,这两种配体的任何一个缺失都会影响上皮细胞分支。鉴于FGF9和FGF10激活不同的FGF受体(FGFRs),研究人员推测它们控制不同的发育过程。经研究发现,FGF9通过上皮FGFR3直接促进远端上皮命运特异性,抑制上

成纤维细胞生长因子(FGFs) 9和10在肺发育的假腺期必不可少。间皮细胞产生的FGF9主要负责间质细胞的生长,而上皮细胞产生的FGF9和间质细胞产生的FGF10则指导肺上皮细胞的发育,这两种配体的任何一个缺失都会影响上皮细胞分支。

鉴于FGF9和FGF10激活不同的FGF受体(FGFRs),研究人员推测它们控制不同的发育过程。经研究发现,FGF9通过上皮FGFR3直接促进远端上皮命运特异性,抑制上皮分化。相反,FGF10通过上皮FGFR2b促进上皮细胞增殖和分化。而且,FGF9-FGFR3信号在功能上与FGF10-FGFR2b信号的相反,FGFR3优先使用下游的PI3K信号通路,而FGFR2b则依赖于下游的MAPK信号通路。

这些数据表明,在肺上皮细胞内,不同FGFRs的功能各不相同;它们与受体特异性的配体结合,通过激活不同的下游信号通路来指导不同的发育功能。

原始出处:

Yongjun Yin and David M. Ornitz.FGF9 and FGF10 activate distinct signaling pathways to direct lung epithelial specification and branching.Science Signaling  03 Mar 2020:Vol. 13, Issue 621, eaay4353 DOI: 10.1126/scisignal.aay4353

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-11-06 yaanren
  2. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-06-05 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-03-07 neurowu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-03-07 liuyiping
  6. [GetPortalCommentsPageByObjectIdResponse(id=1794018, encodeId=8e671e94018d3, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Nov 06 11:11:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036202, encodeId=ec7620362026e, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Fri Jun 05 18:11:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347458, encodeId=7052134e458c2, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483069, encodeId=4f4c1483069b1, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539765, encodeId=8c7f1539e6541, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Mar 07 03:11:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]

相关资讯

JCO:BGJ398治疗FGFR改变晚期胆管癌

对于一线吉西他滨治疗失败的胆管癌患者尚无标准治疗方法。FGFR融合/易位约在13%-17%肝内胆管癌中出现。BGJ398是一种口服的选择性pan-FGFR酶抑制剂,在临床前实验中对FGFR改变肿瘤具有治疗效果。JCO近期发表了一篇文章,研究BGJ398治疗FGFR改变胆管癌患者的临床疗效。

MOL CANCER THER:肺癌治疗的新希望出现

墨尔本的一项研究旨在改善第二大常见类型肺癌——肺鳞状细胞癌患者的治疗方案,肺癌是迫切需要新的抗癌药物的疾病。 研究人员展示了一种更好的方法来招募合适的参与者,以期为抗癌药物FGFR(成纤维细胞生长因子受体)抑制剂提供新的抗癌药物,该药物正在研究用于治疗肺鳞状细胞癌。

成纤维细胞生长因子受体(FGFR)抑制剂pemigatinib治疗胆管癌获得FDA的优先审查

Incyte公司的Pemigatinib用于先前治疗过的局部晚期或转移性胆管癌,已被美国食品和药物管理局(FDA)授予优先审查。

强生的膀胱癌靶向治疗药物Balversa在美国获批

强生的膀胱癌药物Balversa在美国获得批准,用于治疗成纤维细胞生长因子(FGFR)突变的膀胱癌患者。大约有五分之一的复发/难治性膀胱癌患者中存在FGFR基因突变。

Lancet Oncol:Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤

Rogaratinib具有良好的耐受性和临床抗多种类型癌症的活性,有望成为新型广谱抗肿瘤药物

PLoS ONE:阻断FGFR抑制肿瘤转移

成纤维细胞生长因子受体(FGFR)对肿瘤的生长和癌症病人的生存起着至关重要的作用。相比于其他受体酪氨酸激酶,科学家也一直将成纤维细胞生长因子(成纤维细胞生长因子)作为一种治疗癌症的靶标来开展研究。 近日,研究发现FGFR信号抑制后对原位乳腺66c14癌模型肿瘤生长、转移和淋巴血管形成的影响。体外研究表明FGFR抑制后,66c14细胞增殖比对照组慢。小鼠植入FGFR表达抑制的肿瘤细胞后,66c14

Baidu
map
Baidu
map
Baidu
map